Citron Recent News
The Long And The Short Of It: Bitcoin Bull, Bear Weigh In On Huge Move
Veritone Comes Crashing Back To Earth
'All Timing': Citron Covers Helios And Matheson Short
The Polarizing Story That Is Shopify
Citron's Andrew Left Hits The Airwaves To Explain His Bullish BlackBerry Stance
Andrew Left Doubles Down On Wayfair Thesis
Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen
Mallinckrodt Spikes On Citron Tweet
Citron: Mallinckrodt Makes Valeant Look Like Choirboys
Buy The Dip In j2 Global, Susquehanna Says
Fitbit On The Rise As Citron Comes Out Positive
Tesla Short Sellers Paying Much Higher Interest To Bet Against Company
Tesla's Apparent Oil Correlation Doesn't Make Stock A Buy: Why Citron Is Short
Valeant Gets Closer To Left's $50 Target After New Accounting Fears
Critical Of Monster's Valuation, Citron Anticipates A Drop To $80
EXCLUSIVE: Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds
JPMorgan Analyst Defends Valeant, Cites Continued Performance Of Two-Thirds Revenue
Mallinckrodt The Latest To Feel Citron's Wrath, Has Significantly More Downside Than Valeant
Valeant Pharmaceuticals Trading Higher
Valeant Denies Citron's 'Erroneous' Report; Analysts Also Cast Doubt
Citron Calls Valeant The 'Pharmaceutical Enron,' Sees 60% Downside In Stock
Citron Research: Don't Bother Senator Sanders, Here's What A Subpoena On Valeant Would Expose